Table 2. Results of antibody testing against HPV 16 L1 capsids in 606 patients with various carcinomas and results of antibody testing against HPV 16 E7 peptides assay carried out in the HPV 16 L1 capsid antibody positive samples.
| N | HPV 16 pos Pos/N (%) | P-valuea | ORb | E7 Pos/N (%) | |
|---|---|---|---|---|---|
| Negative control (no cancer) | 100 | 18/100 (18) | 2/18 (11) | ||
| Negative control (stomach carcinoma) | 54 | 10/54 (18) | 0/9 (0) | ||
| Cervical squamous carcinoma | 51 | 24/51 (47) | <0.001 | 4.00 | 7/24 (29) |
| (1.9–8.4) | |||||
| Tongue carcinoma | 56 | 12/56 (21) | 0.741 | 3/12 (25) | |
| Oropharyngeal carcinoma | 48 | 16/48 (33) | 0.043 | 2.25 | 2/16 (12) |
| (1.0–4.9) | |||||
| Laryngeal carcinoma | 127 | 25/127 (20) | 0.876 | 3/25 (12) | |
| Oesophageal carcinoma | 117 | 20/117(17) | 0/20 (0) | ||
| Squamous cell | 56 | 8/56 (14) | 0.649 | ||
| Adenocarcinoma | 48 | 11/48 (23) | |||
| Others | 13 | 1/13 (8) | |||
| Vaginal carcinoma | 31 | 8/31 (26) | 0.466 | 0/8 (0) | |
| Penile carcinoma | 122 | 46/122 (38) | <0.001 | 2.72 | 5/45 (11) |
| (1.5–4.9) | |||||
| Total | 706 | align="center"179/706(25) | 22/177(12) |
a
Yates corrected.
b
Odds ratio (95% confidence limits).